164 related articles for article (PubMed ID: 1457284)
1. Treatment of systemic sclerosis.
Wigley FM
Curr Opin Rheumatol; 1992 Dec; 4(6):878-86. PubMed ID: 1457284
[TBL] [Abstract][Full Text] [Related]
2. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
3. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
Rook AH; Freundlich B; Jegasothy BV; Perez MI; Barr WG; Jimenez SA; Rietschel RL; Wintroub B; Kahaleh MB; Varga J
Arch Dermatol; 1992 Mar; 128(3):337-46. PubMed ID: 1550365
[TBL] [Abstract][Full Text] [Related]
4. [Systemic scleroderma in children].
Plantin P; Gavanou J; Le Fur JM; Guillet G
Arch Fr Pediatr; 1988 Dec; 45(10):805-8. PubMed ID: 3266459
[TBL] [Abstract][Full Text] [Related]
5. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
Falcini F; Volpi M; Pierattelli M; Taccetti G; Pratesi G; Matucci Cerinich M
Pediatr Med Chir; 1984; 6(5):703-7. PubMed ID: 6535137
[TBL] [Abstract][Full Text] [Related]
6. Systemic sclerosis.
Ng SC
Singapore Med J; 1992 Apr; 33(2):189-92. PubMed ID: 1621127
[TBL] [Abstract][Full Text] [Related]
7. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
Surwit RS; Gilgor RS; Allen LM; Duvic M
Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
[TBL] [Abstract][Full Text] [Related]
8. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
[TBL] [Abstract][Full Text] [Related]
9. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
10. Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.
Henness S; Wigley FM
Curr Opin Rheumatol; 2007 Nov; 19(6):611-8. PubMed ID: 17917543
[TBL] [Abstract][Full Text] [Related]
11. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
[TBL] [Abstract][Full Text] [Related]
12. Treatment of systemic sclerosis.
Medsger TA
Rheum Dis Clin North Am; 1989 Aug; 15(3):513-31. PubMed ID: 2672135
[TBL] [Abstract][Full Text] [Related]
13. Treatment of systemic sclerosis.
Steen VD
Am J Clin Dermatol; 2001; 2(5):315-25. PubMed ID: 11721650
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
Lukác J; Rovenský J; Tauchmannová H; Zitnan D
Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
[TBL] [Abstract][Full Text] [Related]
15. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
16. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
Merkel PA; Herlyn K; Martin RW; Anderson JJ; Mayes MD; Bell P; Korn JH; Simms RW; Csuka ME; Medsger TA; Rothfield NF; Ellman MH; Collier DH; Weinstein A; Furst DE; Jiménez SA; White B; Seibold JR; Wigley FM;
Arthritis Rheum; 2002 Sep; 46(9):2410-20. PubMed ID: 12355489
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of oral methotrexate in the treatment of systemic sclerosis.
Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T
Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983
[TBL] [Abstract][Full Text] [Related]
18. [Systemic sclerosis].
Tamborrini G; Distler M; Distler O
Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072
[TBL] [Abstract][Full Text] [Related]
19. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with D-penicillamine [see comment].
Jimenez SA; Sigal SH
J Rheumatol; 1991 Oct; 18(10):1496-503. PubMed ID: 1765974
[TBL] [Abstract][Full Text] [Related]
20. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
